Research Summary:

• Clinical outcomes in chronic kidney disease and end-stage renal disease
• Novel treatments in hypertension
• Causal pathways modeling in observational analyses
• Clinical trials methodology

Selected Publications:

Tentori F, Blayney M, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK. Mortality risk categories for calcium, phosphorus and parathyroid hormone derived from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Accepted for publication by Am J Kidney Dis, March 08.

Crutchlow MF*, Robinson BM*, Pappachen B, Wimmer N, Cucchiara AJ, Cohen D, Townsend RR. Validation of Steady State Insulin Sensitivity Indices in Chronic Kidney Disease. Diabetes Care. 07;30:1813-8. *Contributed equally

Robinson BM, Joffe MM, Pisoni Rl, Port F, Feldman HI. Revisiting survival differences by race/ethnicity among hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study. J Am Soc Nephrol 06;17:2910-18.

Robinson BM, Joffe MM, Berns JS, Pisoni Rl, Port F, Feldman HI. Anemia and mortality in hemodialysis patients: accounting for morbidity and treatment variables updated over time. Kidney Int 05;68:2323-30.

Feldman HI, Joffe M, Robinson BM, Knauss J, Cizman B, Guo W, Franklin-Becker E, Faich G. Administration of parenteral iron and mortality in hemodialysis patients. J Am Soc Nephrol 04;15:1623-32.

Robinson BM, Friberg RD , Bowers CY, Barkan AL. Acute growth hormone (GH) response to GH-releasing hexapeptide in humans is independent of endogenous GH-releasing hormone. J Clin Endocrinol Metab 1992;75:1121-24.

Barnes DE, Robinson BM, Csernansky JG, Bellows EP. Sensitization versus tolerance to haloperidol-induced catalepsy: multiple determinants. Pharmacol Biochem Behav 1990;36:883-87.